Follow the Adaptive Biotechnologies Corporation stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €3.4bn. The latest transaction was disclosed on 26 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Harlan Robins. The full history is accessible without an account.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,067 of 28,958 companies
33.6
score / 100
Value
30
Quality
37
FCF yld-1.5%
Earn yld-1.5%
EV/EBITDA·
ROE-39%
Gross mgn87%
Net mgn-21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
11,000 shares@ US$15.9947.4% of flowCommonSEC144:0001950047-26-005668
25 of 25 declarations
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a company focused on developing DNA sequencing technologies for the diagnosis and treatment of diseases. It primarily concentrates on applications in immunology and oncology.